Skip to main content
main-content

28-09-2021 | ESMO 2021 | Conference coverage | Video

ctDNA analysis may help to personalize metastatic urothelial carcinoma treatments

Guru Sonpavde outlines the findings of their immunotherapy study supporting a potential role for longitudinal ctDNA profiling to identify suitable therapies for people with metastatic urothelial cancer (4:43).

This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany

Read transcript

Image Credits